Evidence map›Paper›PMID 40741062›Full record

ArticleClinical and experimental vaccine research2025

Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.

Alison Hofmann Church, Soman N Abraham, Herman F Staats, Brandi T Johnson-Weaver

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental vaccine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alison Hofmann ChurchDepartment of Pediatrics, Duke University Medical Center, Durham, NC, USA.ORCID https://orcid.org/0009-0003-6689-0544
Soman N AbrahamDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.ORCID https://orcid.org/0000-0002-1662-2096
Herman F StaatsDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.ORCID https://orcid.org/0000-0003-1039-1087
Brandi T Johnson-WeaverDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.ORCID https://orcid.org/0000-0001-7432-5383

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Mast cell activating adjuvants induce vaccine-specific systemic and mucosal immunity when administered intranasally. Materials and Methods: Mice received intranasal C48/80-adjuvanted pertussis vaccines or subcutaneous aluminum-adjuvanted pertussis vaccines. Immunized mice were challenged with Results: Alum-adjuvanted pertussis vaccines induce Th2 immunity and undetectable IgA responses. Nasal C48/80-adjuvanted pertussis vaccines enhance pertussis-specific serum and mucosal IgA and Th2 and Th17 responses but not Th1 immunity. The C48/80 and CpG adjuvant combination enhances systemic and mucosal pertussis-specific Th1, Th17, and IgA compared to unadjuvanted pertussis vaccines, which may be the desired immune response to protect against pertussis infections. Conclusion: We demonstrate that nasal pertussis vaccines containing C48/80 adjuvants induce pertussis-specific IgA, Th1-, and Th17-associated immunity when combined with CpG, which may be an effective strategy to improve pertussis vaccines.

Indexed as

Bordetella pertussisImmunologic factorsMucosal immunityVaccine

Identifiers

PMID40741062
PMCPMC12303703

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.